26. March 2019
EUR 3 million in series A for the growth and development of Cytena GmbH
The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics.
EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena's single-cell printers.
Freiburg-based Cytena GmbH successfully completes another financing round. I
29. April 2015
cytena, a University of Freiburg spin-off, received EUR 1.1 million of seed capital from HTGF and a private investor
cytena GmbH, headquartered in Freiburg, has developed a device called single-cell printer to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand its marketing and distribution activities.
The single-cell printer, cytena’s newest innovation, is a laboratory device that enables the gentle separation of cells.